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Objective—White matter hyperintensities(WMH) are areas of increased signal on magnetic 
resonance imaging(MRI) scans that most commonly reflect small vessel cerebrovascular disease. 
Increased WMH volume is associated with risk and progression of Alzheimer’s disease(AD). 
These observations are typically interpreted as evidence that vascular abnormalities play an 
additive, independent role contributing to symptom presentation, but not core features of AD. We 
examined the severity and distribution of WMH in presymptomatic PSEN1, PSEN2, and APP 
mutation carriers to determine the extent to which WMH manifest in individuals genetically-
determined to develop AD.
Methods—The study comprised participants(n=299, age=39.03±10.13) from the Dominantly 
Inherited Alzheimer Network, including 184(61.5%) with a mutation that results in AD and 
115(38.5%) first-degree relatives who were non-carrier controls. We calculated the estimated years 
from expected symptom onset(EYO) by subtracting the affected parent’s symptom onset age from 
the participant’s age. Baseline MRI data were analyzed for total and regional WMH. Mixed effects 
piecewise linear regression was used to examine WMH differences between carriers and non-
carriers with respect to EYO.
Results—Mutation carriers had greater total WMH volumes, which appeared to increase 
approximately 6 years prior to expected symptom onset. The effects were most prominent for the 
parietal and occipital lobe, which showed divergent effects as early as 22 years prior to estimated 
onset.
Interpretation—Autosomal dominant AD is associated with increased WMH well before 
expected symptom onset. The findings suggest the possibility that WMH are a core feature of AD, 
a potential therapeutic target, and a factor that should be integrated into pathogenic models of the 
disease.
Introduction
White matter hyperintensities (WMH), visualized as increased signal on T2-weighted 
magnetic resonance imaging (MRI) of the brain are common radiological features of aging. 
Previously thought to reflect benign changes in underlying tissue or radiographic artifacts, 
they have emerged as correlates of cognitive, functional, emotional, and motoric 
abnormalities that emerge in later life1 and have been linked pathologically to small vessel 
cerebrovascular disease, including arteriosclerosis, demyelination and axonal loss due to 
ischemia or neuronal death, cerebral amyloid angiopathy, and microglia activation2. In 
recent years, there has been strong evidence that WMH are associated with the clinical risk 
and symptomatic course of late onset Alzheimer’s disease (LOAD)3. Despite these 
consistent observations, white matter abnormalities are not included in current conceptual 
models of the pathogenesis and biological marker progression of LOAD (e.g., 4). The debate 
on the extent to which WMH represent a core feature of LOAD can be summarized in two 
opposing views. On the one hand, because AD is defined pathologically by the presence of 
Aβ plaques with neuritic plaques and neurofibrillary tangles adding to the severity of the 
changes, white matter damage is considered a comorbidity that does not represent these 
pathologies. On the other hand, WMH predict the clinical onset and course of AD similarly 
to or better than other biological markers of AD5, 6, may in part reflect vascular forms of AD 
pathology, there are viable biological models that implicate small vessel cerebrovascular 
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disease in the deposition of primary AD pathology7, and among individuals with late onset 
dementia, presence of multiple pathologies is more common than not 8–10.
The study of the emergence of WMH - - or any biological markers - - and their contributions 
to LOAD in humans is difficult because the ordering and timing of the biological changes 
that lead to dementia can occur up to decades before the onset of symptoms4, which is 
typically the point when human studies of LOAD are conducted. White matter 
hyperintensity severity is also tightly linked to vascular risk factors and age2, so 
determination of its contribution to late onset AD is potentially confounded by these factors. 
To overcome these issues, we turned to the landmark Dominantly Inherited Alzheimer 
Network (DIAN) study. The study enrolls individuals at 50% risk for autosomal dominant 
AD by virtue of having a first-degree relative with a pathogenic mutation in one of three 
AD-causing genes: amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 
(PSEN2). Pathogenic mutations are virtually fully penetrant, leading to 100% probability 
that the mutation carrier will develop early onset AD. Although autosomal dominant forms 
of AD account for fewer than 1% of all AD cases, there is strong overlap in symptomatology 
with LOAD, and a recent critical DIAN study established that the order of biological 
changes begins with deposition of amyloid, followed by neurodegenerative changes (e.g., as 
indexed by levels of tau protein in the cerebrospinal fluid [CSF]), and cognitive decline 11. 
Because the age at onset of clinical symptoms is highly heritable among individuals with 
autosomal dominant AD12, parental age at onset can be used as a reliable estimate of clinical 
onset among asymptomatic mutation carriers. Here, we tested the hypothesis that WMH 
burden is elevated among mutation carriers and increases with greater temporal proximity to 
the estimated year of onset of clinical symptoms. Our goal was to determine definitively 
whether WMH are a core feature of AD. Given our previous observations of a WMH 
regional selectivity in LOAD, we also examined the regional distribution of WMH.
Methods
Overall design
The DIAN study (www.dian-info.org; NIA-U19-AG032438) is an international effort that 
includes sites in USA, UK, Germany, and Australia. The study recruits individuals from 
families with a known autosomal dominant mutation for AD, including APP, PSEN1, and 
PSEN2, irrespective of their own mutation status. As part of the DIAN Observational Study, 
participants receive a baseline assessment with sampling of blood and CSF, clinical 
assessment, neuropsychological evaluation, and neuroimaging, and are followed 
longitudinally with identical assessments. Full procedures for the study are described 
elsewhere11, 13. All study procedures received approval from each participating institution 
and all participants gave informed consent.
Clinical assessment
All evaluation procedures were conducted by individuals unaware of the mutation status of 
each participant. The clinical assessment included evaluation with the Clinical Dementia 
Rating scale (CDR)14, physical and neurological examination, neuropsychological testing, 
and determination of the parental age at onset. Parental age at onset was determined with a 
Lee et al. Page 4
Ann Neurol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
semi-structured interview that assessed the age at which the affected parent began exhibiting 
signs of progressive cognitive decline 11. Estimated years from expected symptom onset 
(EYO) were calculated as the difference between the participant’s age and the parental age 
at onset11. This variable was established for all participants regardless of their own mutation 
status. Data included in the present study were a subset from Data Freeze 6 with available 
T2-weighted magnetic resonance imaging (MRI) scans. Remote or current history of 
hypertension, hypercholesterolemia, diabetes, and smoking (≥ 100 cigarettes smoked in 
lifetime) was ascertained via interview and considered in secondary analyses.
Biochemical and genetic analysis
Cerebrospinal fluid was collected via lumbar puncture on each participant under fasting 
conditions11. Samples were shipped to the DIAN biomarker core laboratory and 
immunoassay (INNOTEST β-Amyloid1-42 and INNO-BIA AlzBio3) was used to measure 
CSF concentrations of Aβ1-42 and phosphorylated tau (ptau181). All samples underwent 
quality control procedures11. Each participant’s mutation status and APOE genotype was 
determined according to procedures in the published DIAN protocol11, 13.
Brain imaging
Participants received structural MRI. For the current study, we quantified WMH on T2-
weighted fluid attenuated inversion recovery (FLAIR) structural MRI scans. Scan 
acquisition took place on pre-qualified 3T scanners at each site. Harmonization and quality 
assurance across platforms, sites, and acquisition times followed the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) protocols15. The neuroimaging core laboratory reviewed 
each MRI scan to ensure compliance with the acquisition protocol and image quality. 
Standardized FLAIR sequences (TR:9000, TE:90, TI: 2500, voxel dimensions: 0.86 × 0.86 × 
5.0 mm) were acquired as part of the DIAN MRI protocol. The FLAIR images were 
transferred to Columbia University for WMH quantification using procedures previously 
described16. Briefly, a study-specific intensity threshold was applied to each image to label 
voxels falling within the WMH intensity distribution. An expert operator reviewed and 
edited every image if necessary. A “lobar” atlas was co-registered linearly to each labeled 
FLAIR image to define WMH volumes in frontal, temporal, parietal, and occipital lobes. 
White matter hyperintensity volume was defined as the sum of the labeled voxels multiplied 
by voxel dimensions; regional volumes were calculated within each labeled lobar region-of-
interest. In a random subset of 10 participants, test-retest reliability was greater than 0.98 for 
regional and total WMH volumes. All imaging analyses were completed without knowledge 
of mutation status and demographic and clinical data.
In a subset of participants, T2*-weighted MR images were analyzed at the Mayo Clinic 
(Rochester, MN) for presence of cerebral microbleeds. We operationally defined possible 
cerebral amyloid angiopathy (CAA) as the presence of at least one cerebral microbleed 
according to the Boston criteria17. We examined whether the presence of cerebral 
microbleeds mediated the hypothesized relationship between WMH and mutation status.
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Statistical analysis
Demographic and clinical variables were compared between mutation carriers and non-
carriers with t-tests and Chi-squared analysis for continuous and categorical data, 
respectively. We explored the relationship between total WMH volume and CSF-derived AD 
biomarkers with Spearman’s rank order correlations stratified by mutation status. To test 
whether WMH volume differed by mutation type, we used a general linear model that 
examined the interaction between Carrier Status (carrier vs. non-carrier) and familial 
Mutation Type (PSEN1, PSEN2, APP). We employed piecewise linear mixed effect 
regression with an inflection point as a parameter18 to examine the total and regional WMH 
volumes with respect to estimated years from symptom onset, controlling for participant 
family as a random effect. The primary parameter of interest was the interaction between 
Mutation Status and EYO, which would demonstrate that WMH volume is increasing among 
mutation carriers at a rate that is greater than non-mutation carriers. The inclusion of the 
inflection point as an additional parameter, in the context of a significant interaction, tests 
whether there is a point within the time period at which at which the association between 
EYO and WMH volume begins to diverge between mutation carriers and non-carriers. The 
inflection point was selected based on Bayesian Information Criterion (BIC)19; we tested 
whether the inclusion of the inflection point significantly improved the model fit compared 
with the model without the inflection point with the likelihood ratio test (LRT)20. Overall 
model fits were also determined with the LRT. Similar analyses were run with CSF 
measures of Aβ1-42 (a marker of β-amyloid), ptau181 (a presumed marker of neurofibrillary 
tangles), and the ratio of Aβ1-42 to ptau181, in order to compare the timing and ordering 
among the biomarkers. Analyses involving WMH were also re-run controlling for ptau181 
(Model 2) or Aβ1-42 (Model 3). Analyses were re-run after the inclusion of participant age 
and APOE-ε4 status as additional covariates to ensure that the primary observations were 
not confounded by these factors. Similarly we compared vascular risk histories between 
mutation carriers and non-carriers and computed a vascular risk summary score by adding 
the dichotomous variables together. This score was considered as a covariate in subsequent 
analyses. For visualization, LOESS regression analysis21 was conducted and the estimates 
and their 95% confidence limits were drawn. Statistical analyses were conducted with the 
use of the PROC MIXED and SGPLOT procedures in SAS software, version 9.3 (SAS 
Institute). We tested the differences in total and regional WMH volumes in individuals with 
CDR scores of 0 with a general linear model, adjusting for participant’s age, to ensure that 
differences between groups were not related to the inclusion of symptomatic individuals. 
Prior to statistical analyses, total and regional WMH volumes underwent inverse hyperbolic 
transformation because the distributions of these variables were highly positively skewed22.
Similar mixed effects piecewise linear regression and formal testing of mediation was used 
to examine differences between carriers and non-carriers in presence of cerebral microbleeds 
and to test the whether the association between WMH and mutation status is dependent on 
the presence of cerebral microbleeds.
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Results
Data from 299 participants of the total DIAN cohort that had passed rigorous quality 
assurance for Data Freeze 6 were included in these analyses (see Table 1 for demographic, 
clinical, and biomarker data). There were 184 (61.5%) mutation carriers, including 141 
(77%) PSEN1, 15 (8%) PSEN2, and 28 (15%) APP mutation carriers. Mutation carriers and 
non-carriers were almost identical in age, sex distribution, vascular risk factors, EYO, and 
frequency of APOE-ε4, but had a greater proportion of symptomatic individuals (i.e., 
CDR>0). Mutation carriers had greater total, temporal, parietal, and occipital WMH 
volumes than non-carriers; these differences between mutation carriers and non-carriers 
remained when restricting the sample to asymptomatic participants (i.e., CDR=0; p<0.05 for 
total and occipital lobe, p=0.09 for parietal lobe, p=0.11 for temporal lobe). Differences in 
WMH volume between mutation carriers and non-carriers were not driven by a single 
mutation type, as evidenced by a significant main effect of Carrier Status (p<0.05) for all 
regions apart from frontal lobe, and non-significant interactions (p>0.05) between Carrier 
Status and Mutation Type for all regions. As expected, mutation carriers had lower levels of 
Aβ1-42 and higher levels of ptau181 compared with non-carriers; these differences remained 
(p<0.001) when restricting the sample to individuals with CDR scores of 0. Increased total 
WMH volume was associated with lower Aβ1-42 levels in mutation carriers (r=−0.190, 
p=0.01) but not in non-carriers (r=−0.053, p=0.623; see Figure 1). White matter 
hyperintensity volume was not related to ptau181 levels in mutation carriers (r=−0.090, 
p=0.162) or in mutation non-carriers (r=−0.025, p=0.813). Descriptive statistics for WMH 
volume, including median, first quartile, third quartile, and interquartile range are presented 
in Table 2.
Results of the piecewise linear mixed effect analyses revealed a reliable increase in total 
WMH volume among mutation carriers (significant Mutation Status by EYO interactions) 
with an inflection point occurring approximately 6.6 years prior to estimated symptom onset 
(EYO−6.6; see Figure 2 and Supplementary Table). When we examined the regional 
distribution of WMH, significant effects emerged in the parietal and occipital lobes. For the 
parietal lobe, much like total WMH volume, the inflection point occurred approximately 
seven years prior to estimated symptom onset (EYO −7). For the occipital lobes, the 
inflection point occurred approximately 22 years prior to estimated symptom onset (EYO 
−22; see Figure 3). Cerebrospinal fluid levels of Aβ1-42, ptau181, and Aβ1-42 to ptau181 
ratio levels appeared to diverge in mutation carriers approximately 30, 26, and 29 years prior 
to estimated symptom onset, respectively. Thus, in terms of ordering and staging, the results 
suggest that total WMH volumes are increased reliably after amyloid and tau abnormalities 
are detectable but prior to symptom onset. Regionally, posterior WMH volume increases in 
mutation carriers at about the same time that CSF ptau181 and CSF amyloid changes occur. 
When adjusting for CSF AD biomarkers, total WMH volumes remained significantly 
elevated in mutation carriers when controlling for ptau181 levels but not when controlling 
for Aβ1-42 levels. Figure 4 displays representative examples of WMH in mutation carriers 
and non-carriers across three EYO time points. When all analyses were repeated with age 
and APOE-ε4 status as additional covariates (data not shown) none of the primary 
observations were altered and the additional covariate parameters were not statistically 
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significant. Similarly, when the analyses were re-run with the vascular risk summary score 
none of the primary observations changed. When we examined the potential contribution of 
CAA among a subset of participants (n=175), we found that mutation carriers were more 
likely to have cerebral microbleeds than non-carriers (20% vs. 6%, p<0.05) and individuals 
with microbleeds had higher WMH volume than those without (p<0.05). White matter 
hyperintensity volume was increased in mutation carriers, up to 20 years prior to EYO, after 
controlling for microbleed status. Total WMH also remained significantly elevated in 
mutation carriers even after exclusion of individuals with microbleeds from the study 
sample. Formal testing of mediation demonstrated that 21% of the association between 
mutation status and WMH was mediated by presence of microbleeds (p=0.03) but a 
significant direct effect of WMH remained (p=0.02) after controlling for presence of 
microbleeds.
Discussion
We found that total WMH volume is significantly elevated among individuals with 
autosomal dominant genetic mutations for AD approximately six years prior to their 
estimated age of symptom onset. When considered regionally, WMH volume distributed in 
posterior brain areas is selectively elevated among mutation carriers about 22 years prior to 
estimated symptom onset. Together with the previous studies that have implicated WMH, 
particularly in posterior regions, in risk and progression of clinical symptomatology of 
LOAD 16, 23, our study suggests that WMH are an important feature of AD. Because 
mutation carriers and non-carriers in the current study are relatively young, virtually 
identical demographically, and at identical risk for inheriting an autosomal dominant 
mutation by virtue of having a parent with a mutation, the findings provide strong evidence 
that WMH in this population do not reflect comorbidity or other pathophysiology but rather 
reflect primary pathogenic processes in AD. The results highlight the potential role of 
regionally distributed WMH in AD and point to new avenues of investigation for 
preventative or treatment strategies.
In the context of other AD biomarkers, WMH appear to emerge globally after measurable 
changes in CSF Aβ1-42 and ptau181 but prior to symptom onset, although WMH distributed 
in posterior brain areas appear elevated at about the same time as tau and Aβ1-42 differences. 
These findings should be interpreted in the context of wide confidence intervals, and 
therefore relatively lower reliability, related to the inflection point analyses. White matter 
hyperintensity volume correlated with CSF Aβ1-42 but not ptau181, and when controlling for 
Aβ1-42 in our primary analyses, elevation of WMH associated with mutation status was 
attenuated. These results first suggest that WMH and beta amyloid pathology share some 
degree of dependency. We24 and others25, 26 have shown previously that WMH volume and 
markers of fibrillar amyloid pathology are related to each other in the context of LOAD, 
though others have not27. This study confirms that the two biomarkers are related to each 
other in individuals with definite pre-clinical AD. Second, they suggest that WMH do not 
result primarily from tau-related neurodegeneration, although the extent to which WMH are 
related to axonal damage secondary to tau abnormalities cannot be ruled out entirely by 
these analyses. We showed in ADNI that WMH severity predicts future CSF tau increases 
and neurodegenerative changes but that CSF tau levels do not predict future WMH 
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accumulation28. We found that CSF Aβ1-42is levels appear to be initially higher followed by 
a rapid decline as a function of EYO in mutation carriers compared with non-carriers (see 
Figure 3), suggesting that Aβ1-42 are abnormally elevated and begin to decline prior to 
increases in tau. It is important to note that because the analyses were cross-sectional, the 
determination of an inflection point was estimated and variable, and we were unable to 
model the subject-specific trajectories, which would require longitudinal data. Nonetheless, 
in all cases but one (the statistical model in which we controlled for Aβ1-42, see 
Supplementary Table), inclusion of the inflection point significantly improved the model fit. 
Furthermore, our approach determined definitively that the relationship between estimated 
time to symptom onset and WMH volume differed between mutation carriers and non-
carriers (i.e., significant Mutation Status by EYO interactions) and, much like previous work 
in DIAN 11, allowed us to compare the evolution of WMH compared with the other 
biological markers.
White matter hyperintensities are generally considered markers of small vessel 
cerebrovascular disease29, 30, although it is important to point out that non-ischemic damage 
that causes increased fluid motion in discrete areas in the white matter can result in 
hyperintense signal. Pathogenic mechanisms are not known completely, but a recent genetic 
meta-analysis suggested a role of blood pressure regulation, Aβ-related neurotoxicity, 
neuroinflammation, and glial cell activation31. Pathological correlates, 
immunohistochemical, and gene expression studies suggest demyelination, axonal loss, 
gliosis, vacuolation, microglial activation, arteriolosclerosis, and blood brain barrier 
dysfunction are secondary to ischemic injury in areas appearing radiographically as WMH 2. 
The pathophysiology of WMH is likely heterogeneous and only one study to our knowledge 
has examined the pathological correlates of WMH among individuals with autosomal 
dominant forms of AD, in whom the mediators of WMH might differ somewhat32. In that 
report, WMH burden correlated with the severity of cerebral amyloid angiopathy in the 
temporal lobes, leptomeningeal blood vessel diameter, and lower density of CD68-positive 
microglia in the parietal lobes among 10 individuals with PSEN1 mutations. Given the 
propensity for a posterior distribution of WMH we found in mutation carriers, cerebral 
amyloid angiopathy, which also tends to be distributed in posterior brain regions, is present 
among individuals with autosomal dominant forms of AD years before symptoms onset, and 
correlates with severity of WMH33, may be one mediating factor in these observations. 
Similarly, one previous report suggests that the WMH severity correlates with severity of 
fibrillar forms of amyloid pathology among individuals with CAA but not LOAD34, again 
suggesting an influence of CAA on the observed relationship between WMH volume and 
Aβ1-42 levels, and we could speculate that CAA may be one causative factor in the 
parenchymal deposition of Aβ. Although in the current study there was some co-dependency 
between WMH and presence of at least one cerebral microbleed, the observed increases in 
WMH among mutation carriers did not appear to be fully mediated by this marker of 
cerebral amyloid angiopathy. Loss of axons, myelin pallor, and diffuse Aβ has also been 
observed pathologically in the white matter of patients with autosomal dominant AD and 
LOAD and in animal models of the disease35–38. Alzheimer’s-related failure of the axonal 
machinery due to mitochondrial dysfunction, white matter astroglial proliferation, venous 
collagenosis, and damage to oligodendrocytes and their progenitor cells are other possible 
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pathological correlates of our results36, 39–42. Clearly more work relating radiological white 
matter abnormalities to pathological phenomena is necessary.
White matter hyperintensities are quite common in normal aging43 and have been implicated 
in non-Alzheimer’s forms of cognitive impairment and dementia44. Thus, the question of the 
extent to which WMH represent a specific biomarker for AD or for its clinical instantiation 
is valid and consistent with the conceptualization of other AD biomarkers. For example, 
increased beta amyloid pathology is observed in up to 40% of older individuals with no 
evidence of dementia 45, 46; tau pathology is common in aging, in several neurodegenerative 
diseases, and in chronic traumatic brain injury 47–49, albeit with differing regional patterns 
across conditions; and regional atrophy is characteristic of LOAD 50, but is also common in 
normal aging 51. Our observations, together with previous work that has implicated WMH in 
late onset AD, suggest the possibility that WMH could be incorporated more formally into 
proposed hypothetical models of disease pathogenesis, such as those proposed by Jack and 
colleagues4. The definitive relationship we observed between increased WMH and 
autosomal dominant forms of AD should motivate continued research on the involvement of 
white matter abnormalities with the disease, including examination of mechanistic 
interactions with other putative AD biomarkers.
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Figure 1. 
Correlation between total WMH volume and Aβ1-42, plotted separately for mutation carriers 
and non-carriers. The relationship was significant (r=−0.26, p=0.0012) for carriers but not 
for non-carriers (r=−0.053, p=0.623). Shaded areas represent 95% confidence intervals. 
IHS=inverse hyperbolic sine transformation.
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Figure 2. 
Association between estimated year from symptom onset and total WMH volume in 
mutation carriers and non-carriers. Mutation carriers had greater total WMH volume; 
differences in WMH volume between groups began increasing systematically approximately 
6.6 years prior to estimated symptom onset (inflection point: −6.6 EYO, indicated by arrow 
on x-axis). Shaded areas represent 95% confidence intervals. Arrow indicates the inflection 
point in the analysis. IHS=inverse hyperbolic sine transformation.
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Figure 3. 
Association between estimated year from symptom onset and regional WMH volumes and 
AD biomarkers in mutation carriers and non-carriers. In all cases, mutation carriers had 
more severe biomarker burden; the point at which differences between groups begin to 
increase systematically (i.e., inflection point) is indicated by an arrow on the x-axis. A: 
frontal lobe WMH volume (inflection point=−3.0 EYO); B: temporal lobe WMH volume 
(inflection point=−1.3 EYO); C: parietal lobe WMH volume (inflection point=−7.0 EYO); 
D: occipital lobe WMH volume (inflection point=−22.0 EYO); E: Aβ42 (inflection point=
−30.1 EYO); F: ptau181 (inflection point=−26.0 EYO). Shaded areas represent 95% 
confidence intervals. IHS=inverse hyperbolic sine transformation.
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Figure 4. 
Examples of WMH distribution in mutation carriers (upper row) and non-carriers (lower 
row) across three EYO time points. The top row displays examples of T2-weighted FLAIR 
MRI scans from three mutation carriers at varying estimated years from symptom onset. The 
bottom row displays examples of MRI scans from non-carriers matched for estimated years 
from symptom onset (based on parental age of onset). All participants displayed in this 
figure had CDR scores of 0 at the time of MRI scan.
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